Gene therapy, with the potential to revolutionize healthcare, is facing its own set of trials and tribulations. The high costs and limited accessibility of such therapies, coupled with commercialization challenges and regulatory hurdles, have put this promising sector under the spotlight. However, FDA leaders, who have pledged their unwavering support, are set to change the […]
Tag: Gene Therapy
Second DMD Patient Fatality from Sarepta Gene Therapy
In the high-stakes and high hopes world of biotech, the journey to groundbreaking therapies is often marked by triumphs and tribulations. A recent incident in this field, involving the gene therapy of Sarepta Therapeutics, paints a clear picture of these contrasting realities. The company has announced a temporary suspension of shipments for its flagship gene […]
Regulatory Progress for AMT-130 Gene Therapy in Huntington’s Disease
Amid the unrelenting quest for disease-modifying treatments, uniQure’s groundbreaking progress with the FDA on an accelerated approval pathway for AMT-130 gene therapy in Huntington’s disease has set the biotech industry abuzz. A shift in the composite Unified Huntington’s Disease Rating Scale (cUHDRS) as an intermediate clinical endpoint, combined with the use of natural history external […]
Dual-Vector Strategies for Large Transgene Gene Therapy
In the high-stakes game of gene therapy, adeno-associated virus (AAV) vectors have been the go-to workhorses. These vectors have the ability to deliver a therapeutic gene to a patient’s cells, offering hope for the treatment of genetic disorders, such as Duchenne muscular dystrophy, hemophilia A, and certain retinal degeneration disorders. But, akin to a mail […]
Analyzing Taysha Gene Therapies’ Position
Taysha Gene Therapies Inc. is carving an indelible mark within the gene therapy landscape, specializing in the treatment of monogenic Central Nervous System (CNS) diseases. Distinguished by its innovative approach, Taysha is driving forward with the development of Adeno-Associated Virus (AAV)-based gene therapies, targeting both rare and common CNS disorders. The company’s trailblazing efforts are […]
Advancing Protein Splicing Medicines with $135M Series B Funding
In the high-stakes world of gene therapy, Barcelona-based SpliceBio has carved a unique path by focusing on delivering replacement proteins for mutated genes. This innovative approach is a refreshing departure from traditional gene splicing or editing techniques, and it’s making waves in the biotech community. At the heart of their groundbreaking work is SB-007, a […]
Sarepta Therapeutics: Gene Therapy Challenges and Future
In the ever-evolving world of biotechnology, the unexpected can often be the catalyst for significant change. This is the case for the Duchenne muscular dystrophy (DMD) community following the tragic death of a patient linked to Sarepta Therapeutics’ gene therapy, Elevidys. This event, as dissected in a recent report by Jason Mast and colleagues at […]
Regenxbio’s DMD Gene Therapy Falls Short of Elevidys
In the fiercely competitive space of Duchenne muscular dystrophy (DMD) gene therapy, Regenxbio’s latest data on RGX-202 has drawn significant attention. However, contrary to high expectations, it appears to match, rather than outperform, Sarepta’s Elevidys, which received approval in June 2023. This comes despite promising interim Phase I/II results from the AFFINITY DUCHENNE trial. The […]
Expert Analysis of Regenxbio by 8 Analysts
In the dynamic landscape of biotech innovation, Regenxbio Inc. stands tall as a beacon of hope for those burdened by genetic defects. This biotech company is trailblazing a path in the development and commercialization of recombinant adeno-associated virus gene therapy, positioning it at the forefront of revolutionary therapeutic techniques. Regenxbio’s game-changing platform is designed to […]
Rare Disease and Gene Therapy Threatened by Tariffs
In the face of mounting tariff threats from the Trump administration, the biotech industry has sounded a fervent alarm. The sector warns that advancements in rare disease, cell, and gene therapies—areas where innovation is sorely needed—are under serious threat. The issue at stake is not just about dollars and cents, but the broader public health […]
Latest Innovations in Viral Vector Design and AI
Viral vectors remain the cornerstone of modern gene therapy, enabling targeted delivery of therapeutic genes to specific tissues. As the pipeline of gene- and cell-based therapies expands, the complexity of vector engineering and manufacturing has surged. In response, artificial intelligence (AI) and machine learning (ML) are transforming the design, optimization, and scale-up of viral vectors, […]
Gene Therapy 2.0: The Blueprint for Tomorrow’s Medicine
Gene therapy stands at the forefront of modern medicine, offering unprecedented opportunities to treat and potentially cure a myriad of diseases by addressing their genetic foundations. This innovative approach involves the manipulation of genetic material within a patient’s cells to correct malfunctioning genes, introduce new genes, or modify gene expression. As research progresses, gene therapy […]
